vs
Side-by-side financial comparison of RenovoRx, Inc. (RNXT) and ATIF Holdings Ltd (ZBAI). Click either name above to swap in a different company.
ATIF Holdings Ltd is the larger business by last-quarter revenue ($250.0K vs $238.0K, roughly 1.1× RenovoRx, Inc.). ATIF Holdings Ltd runs the higher net margin — -635.6% vs -1235.7%, a 600.1% gap on every dollar of revenue.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapy delivery systems for cancer treatment. Its core assets include proprietary transarterial delivery platforms, with primary operations in the United States, serving unmet medical needs in the oncology care segment.
ATIF Holdings Ltd is a professional business advisory service provider that mainly serves small and medium-sized enterprises across the Asia-Pacific region. It offers corporate strategic consulting, fundraising guidance, cross-border expansion support, and industry resource matching services for clients in technology, consumer goods, manufacturing and other key sectors.
RNXT vs ZBAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $238.0K | $250.0K |
| Net Profit | $-2.9M | $-1.6M |
| Gross Margin | 88.2% | — |
| Operating Margin | -1479.8% | -75.6% |
| Net Margin | -1235.7% | -635.6% |
| Revenue YoY | — | 25.0% |
| Net Profit YoY | -2.2% | -96.8% |
| EPS (diluted) | $-0.08 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $238.0K | — | ||
| Q3 25 | $266.0K | — | ||
| Q2 25 | $422.0K | $250.0K | ||
| Q1 25 | $197.0K | $200.0K | ||
| Q3 24 | — | $270.0K | ||
| Q2 24 | — | $200.0K | ||
| Q1 24 | — | $25.0K | ||
| Q4 23 | — | $125.0K |
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | $-2.9M | $-1.6M | ||
| Q1 25 | $-2.4M | $-1.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-807.6K | ||
| Q1 24 | — | $-407.6K | ||
| Q4 23 | — | $-625.5K |
| Q4 25 | 88.2% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 64.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | -1479.8% | — | ||
| Q3 25 | -1203.0% | — | ||
| Q2 25 | -634.6% | -75.6% | ||
| Q1 25 | -1578.7% | -175.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -260.6% | ||
| Q1 24 | — | -2190.1% | ||
| Q4 23 | — | -525.4% |
| Q4 25 | -1235.7% | — | ||
| Q3 25 | -1094.7% | — | ||
| Q2 25 | -686.0% | -635.6% | ||
| Q1 25 | -1228.4% | -951.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -403.8% | ||
| Q1 24 | — | -1630.6% | ||
| Q4 23 | — | -500.4% |
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.08 | $-0.09 | ||
| Q1 25 | $-0.08 | $-0.16 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.04 | ||
| Q4 23 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $7.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.4M | $8.4M |
| Total Assets | $8.1M | $8.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $12.3M | $7.8M | ||
| Q1 25 | $14.6M | $8.0M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | $139.2K | ||
| Q4 23 | — | $361.2K |
| Q4 25 | $5.4M | — | ||
| Q3 25 | $8.1M | — | ||
| Q2 25 | $10.6M | $8.4M | ||
| Q1 25 | $13.2M | $7.9M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $506.3K | ||
| Q4 23 | — | $913.9K |
| Q4 25 | $8.1M | — | ||
| Q3 25 | $11.2M | — | ||
| Q2 25 | $13.6M | $8.7M | ||
| Q1 25 | $16.0M | $8.6M | ||
| Q3 24 | — | $3.0M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $2.5M | ||
| Q4 23 | — | $3.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.0M | $-939.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $-2.3M | — | ||
| Q2 25 | $-2.3M | $-939.0K | ||
| Q1 25 | $-3.4M | $-395.1K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-62.6K | ||
| Q1 24 | — | $-212.8K | ||
| Q4 23 | — | $195.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-3.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-213.5K | ||
| Q4 23 | — | $191.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -1717.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -854.1% | ||
| Q4 23 | — | 152.8% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 3.0% | ||
| Q4 23 | — | 3.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
